Guiyang Xintian Pharmaceutical Co Ltd
SZSE:002873
Guiyang Xintian Pharmaceutical Co Ltd
SZSE:002873
Price:
10.8
CNY
-4.59%
Market Closed
Market Cap:
¥2.5B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Guiyang Xintian Pharmaceutical Co Ltd
SZSE:002873
|
CN |
|
A
|
AFP Cuprum SA
SGO:CUPRUM
|
CL |
|
Seacoast Banking Corporation of Florida
NASDAQ:SBCF
|
US |
|
Narumiya International Co Ltd
TSE:9275
|
JP |
|
Allied Properties Real Estate Investment Trust
TSX:AP.UN
|
CA |
|
D
|
DCM Financial Services Ltd
NSE:DCMFINSERV
|
IN |
|
C
|
Coinbase Global Inc
XETRA:1QZ
|
US |
|
K
|
Kellanova
SWB:KEL
|
US |
|
Parex Resources Inc
TSX:PXT
|
CA |
|
Dynemic Products Ltd
NSE:DYNPRO
|
IN |
|
C
|
Cryo-Cell International Inc
AMEX:CCEL
|
US |
|
Alvopetro Energy Ltd
XTSX:ALV
|
CA |
|
B
|
Binah Capital Group Inc
NASDAQ:BCG
|
US |
Multiples-Based Value
The Multiples-Based Value of one
Guiyang Xintian Pharmaceutical Co Ltd
stock under the Base Case scenario is
hidden
CNY.
Compared to the current market price of 10.8 CNY,
Guiyang Xintian Pharmaceutical Co Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Guiyang Xintian Pharmaceutical Co Ltd Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
Guiyang Xintian Pharmaceutical Co Ltd Competitors
Guiyang Xintian Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Guiyang Xintian Pharmaceutical Co Ltd
SZSE:002873
|
2.5B CNY | 3.4 | 278.9 | 102.4 | 102.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
887.6B USD | 13.6 | 43 | 29 | 31 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.2B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236.2B GBP | 5.3 | 30.6 | 16.9 | 23.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.6 | 11.6 | 13 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.5B USD | 4.6 | 16.5 | 10.2 | 12.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
234.4B CHF | 5.2 | 21 | 13 | 16.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.1B USD | 2.4 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118B USD | 2.5 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
